1112 patients dosed and no response statistically. Yes as I told you phase 2 and side effects are in the bag for a significant rerate it’s happened many time before. Just let the company progress phase 2 and the same responses as before will be announced. It’s already a winner that’s why I’m in the stock. There is minimal risk involved because the drug class is already proven
1112 patients dosed and no response statistically. Yes as I told...
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
75.0¢ |
Change
-0.010(1.32%) |
Mkt cap ! $96.06M | |||
| Open | High | Low | Value | Volume |
| 76.0¢ | 76.5¢ | 74.5¢ | $38.31K | 50.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | 75.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.5¢ | 9891 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| AGN (ASX) Chart |